Question · asked by 1 review
Cipaglucosidase plus miglustat vs alglucosidase alfa plus placebo: QoL
- Population
- adults with LOPD
- Intervention
- Cipaglucosidase plus miglustat
- Comparison
- alglucosidase alfa plus placebo
- Outcome
- QoL
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Cipaglucosidase plus miglustat vs alglucosidase alfa plus placebo QoL: change from baseline to PROMIS score (physical function score and fatigue score) · adults with LOPD Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane Headline outcomes only | no estimate extracted | 1 study · 121 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.